Compare KRYS & GATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | GATX |
|---|---|---|
| Founded | 2015 | 1898 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Transportation Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 6.1B |
| IPO Year | 2017 | 1994 |
| Metric | KRYS | GATX |
|---|---|---|
| Price | $347.90 | $179.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 2 |
| Target Price | ★ $297.60 | $215.50 |
| AVG Volume (30 Days) | ★ 292.9K | 202.2K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.36% |
| EPS Growth | ★ 128.00 | 17.22 |
| EPS | 1.83 | ★ 2.35 |
| Revenue | $389,130,000.00 | ★ $1,740,400,000.00 |
| Revenue This Year | $38.74 | $42.21 |
| Revenue Next Year | $32.53 | $3.35 |
| P/E Ratio | $185.91 | ★ $75.73 |
| Revenue Growth | ★ 33.94 | 9.77 |
| 52 Week Low | $130.50 | $148.20 |
| 52 Week High | $356.50 | $205.56 |
| Indicator | KRYS | GATX |
|---|---|---|
| Relative Strength Index (RSI) | 70.03 | 54.44 |
| Support Level | $253.89 | $166.31 |
| Resistance Level | N/A | $186.61 |
| Average True Range (ATR) | 12.45 | 3.88 |
| MACD | 2.83 | 1.34 |
| Stochastic Oscillator | 86.45 | 83.57 |
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
GATX Corp leases transportation assets, including railcars, aircraft spare engines, and tank containers, to customers in North America, Europe, and India. The company's reportable business segments are: Rail North America, Rail International, Engine Leasing, and Other. The majority of its revenue is generated from the Rail North America segment, which is composed of the company's operations in the United States, Canada, and Mexico. This segment mainly provides railcars pursuant to full-service leases under which it maintains the railcars, pays ad valorem taxes and insurance, and provides other ancillary services.